We are live on
!
Find out more
DnB Asset Management Portfolio holdings
AUM
$35.7B
Turnover
15.37%
1-Year Est. Return
27.58%
This Fund
S&P 500
This Quarter
Est. Return
+17.11%
1 Year Est. Return
+27.58%
3 Year Est. Return
+110%
5 Year Est. Return
+135.26%
10 Year Est. Return
+538.97%
AUM
$24.1B
AUM Growth
+$2.42B
(+11%)
Cap. Flow
-$553M
Cap. Flow
% of AUM
-2.29%
Top 10 Holdings %
Top 10 Hldgs %
41.39%
Holding
784
New
46
Increased
374
Reduced
265
Closed
68
Avg Time Held
6.1
years
Top 10 Avg Time Held
5.3
years
Top 20 Avg Time Held
3.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$256M |
| 2 |
Mastercard
MA
|
+$201M |
| 3 |
Atlassian
TEAM
|
+$154M |
| 4 |
Salesforce
CRM
|
+$149M |
| 5 |
TSMC
TSM
|
+$138M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$209M |
| 2 |
Take-Two Interactive
TTWO
|
+$207M |
| 3 |
NVIDIA
NVDA
|
+$205M |
| 4 |
Zscaler
ZS
|
+$182M |
| 5 |
Microsoft
MSFT
|
+$146M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.09% |
| 2 | Financials | 13.21% |
| 3 | Communication Services | 12.66% |
| 4 | Consumer Discretionary | 10.19% |
| 5 | Healthcare | 7.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
676
Hims & Hers Health
HIMS
$6.55B
| $281K | ﹤0.01% |
5,635
-105,980
| -95% | -$4.79M |
2024 Q1
5 quarters
|
|
677
DELISTED
Merus
MRUS
| $280K | ﹤0.01% |
5,329
-3,706
| -41% | -$174K |
2025 Q1
1 quarter
|
|
678
Syndax Pharmaceuticals
SNDX
$1.15B
| $275K | ﹤0.01% |
29,362
+6,984
| +31% | +$76.9K |
2024 Q1
5 quarters
|
|
679
Geron
GERN
$752M
| $269K | ﹤0.01% |
190,763
+54,182
| +40% | +$76.8K |
2024 Q3
3 quarters
|
|
680
Arbe Robotics
ARBE
$59M
| $258K | ﹤0.01% |
144,840
| – | – |
2024 Q3
3 quarters
|
|
681
Celldex Therapeutics
CLDX
$2.16B
| $250K | ﹤0.01% |
12,300
-334
| -3% | -$6.5K |
2024 Q1
5 quarters
|
|
682
Disc Medicine
IRON
$2.18B
| $243K | ﹤0.01% |
+4,583
| New | +$215K |
2025 Q2
0 quarters
|
|
683
Tapestry
TPR
$23.8B
| $242K | ﹤0.01% |
+2,758
| New | +$209K |
2025 Q2
0 quarters
|
|
684
Legend Biotech
LEGN
$3.59B
| $241K | ﹤0.01% |
+6,804
| New | +$220K |
2025 Q2
0 quarters
|
|
685
Immunocore
IMCR
$1.51B
| $239K | ﹤0.01% |
7,628
-3,225
| -30% | -$100K |
2024 Q1
5 quarters
|
|
686
Annexon
ANNX
$646M
| $239K | ﹤0.01% |
99,574
+25,195
| +34% | +$50.5K |
2024 Q1
5 quarters
|
|
687
Krystal Biotech
KRYS
$9.37B
| $238K | ﹤0.01% |
1,731
-48
| -3% | -$7.05K |
2024 Q1
5 quarters
|
|
688
Acadia Pharmaceuticals
ACAD
$3.29B
| $236K | ﹤0.01% |
10,919
-4,692
| -30% | -$87.2K |
2024 Q2
4 quarters
|
|
689
Flex
FLEX
$33.4B
| $229K | ﹤0.01% |
+4,596
| New | +$179K |
2025 Q2
0 quarters
|
|
690
DELISTED
Amicus Therapeutics
FOLD
| $225K | ﹤0.01% |
39,241
+3,722
| +10% | +$24K |
2022 Q2
12 quarters
|
|
691
DELISTED
Soleno Therapeutics
SLNO
| $223K | ﹤0.01% |
+2,665
| New | +$199K |
2025 Q2
0 quarters
|
|
692
Structure Therapeutics
GPCR
$1.5B
| $221K | ﹤0.01% |
+10,635
| New | +$234K |
2025 Q2
0 quarters
|
|
693
DELISTED
Vicarious Surgical
RBOT
| $219K | ﹤0.01% |
29,199
+3,154
| +12% | +$22.9K |
2024 Q3
3 quarters
|
|
694
Janux Therapeutics
JANX
$1.01B
| $214K | ﹤0.01% |
9,253
+1,488
| +19% | +$39.2K |
2024 Q2
4 quarters
|
|
695
Biohaven
BHVN
$1.63B
| $214K | ﹤0.01% |
15,137
+5,561
| +58% | +$99.1K |
2024 Q2
4 quarters
|
|
696
Cyngn
CYN
$6.76M
| $211K | ﹤0.01% |
+14,612
| New | +$74.2K |
2025 Q2
0 quarters
|
|
697
Casey's General Stores
CASY
$25.5B
| $209K | ﹤0.01% |
+409
| New | +$188K |
2025 Q2
0 quarters
|
|
698
Insmed
INSM
$21B
| $208K | ﹤0.01% |
+2,062
| New | +$158K |
2025 Q2
0 quarters
|
|
699
Immunovant
IMVT
$5.52B
| $206K | ﹤0.01% |
12,904
-1,452
| -10% | -$22K |
2024 Q1
5 quarters
|
|
700
Affirm
AFRM
$25B
| $202K | ﹤0.01% |
+2,919
| New | +$151K |
2025 Q2
0 quarters
|
|
Similar funds
DnB Asset Management's Q2 2025 Portfolio in Review
As of Q2 2025, DnB Asset Management held 784 positions worth $24.1B, up 11% from $21.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
DnB Asset Management's Q2 2025 filing shows 46 new, 374 increased, 265 reduced and 68 closed positions. Its largest new stake was Spotify: 38,890 shares worth $29.8M. The largest sale was Amazon, an estimated $209M.
By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 37% a quarter earlier, followed by Financials and Communication Services.
- DnB Asset Management's largest Q2 2025 buy was Spotify: 38,890 shares worth $29.8M.
- DnB Asset Management added most to Apple in Q2 2025, an estimated $256M increase.
- DnB Asset Management's biggest Q2 2025 reduction was Amazon, cutting an estimated $209M.
- DnB Asset Management fully exited Vail Resorts in Q2 2025, selling an estimated $29M.
- DnB Asset Management's ten largest holdings make up 41% of its $24.1B portfolio in Q2 2025.
- DnB Asset Management opened 46 new positions and closed 68 in Q2 2025.
- DnB Asset Management's portfolio value rose 11% quarter-over-quarter to $24.1B.
Based on DnB Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.